Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

The Investment Committee give you their top stocks to watch for the second half.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term. On January 12, ...

VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

Detailed price information for Agilon Health Inc (AGL-N) from The Globe and Mail including charting and trades.

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...